Published in Eur Heart J on February 20, 2014
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) | NCT00412984
Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord (2015) 1.52
Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues. J Stroke (2016) 0.85
[New oral anticoagulants for prophylaxis of stroke : Results of an expert conference on practical use in geriatric patients]. Z Gerontol Geriatr (2016) 0.80
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother (2016) 0.80
Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. Curr Cardiol Rev (2014) 0.80
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ (2016) 0.79
Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. Sci Rep (2016) 0.79
Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol (2015) 0.78
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc (2016) 0.78
Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study. Medicine (Baltimore) (2016) 0.77
Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. Int J Gen Med (2015) 0.76
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging (2015) 0.76
Atrial fibrillation management in older heart failure patients: a complex clinical problem. Heart Int (2016) 0.75
Antithrombotic management of atrial fibrillation in the elderly. Med Clin North Am (2015) 0.75
ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age. Ann Intern Med (2014) 0.75
Appropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study. Can J Hosp Pharm (2016) 0.75
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis (2016) 0.75
Individualising Anticoagulant Therapy in Atrial Fibrillation Patients. Arrhythm Electrophysiol Rev (2016) 0.75
Oral Anticoagulants and Renal Impairment: The Convoluting Dilemma. EBioMedicine (2016) 0.75
The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. Indian Heart J (2015) 0.75
Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. J Thromb Thrombolysis (2016) 0.75
Risk impact of edoxaban in the management of stroke and venous thromboembolism. Vasc Health Risk Manag (2016) 0.75
Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. Cardiovasc Drugs Ther (2016) 0.75
Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians. Clin Interv Aging (2017) 0.75
Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa). J Arrhythm (2016) 0.75
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015. Acta Pharm Sin B (2016) 0.75
ACP Journal Club. In AF, apixaban reduced stroke or systemic embolism compared with warfarin, regardless of patient age. Ann Intern Med (2014) 0.75
Left Atrial Appendage Thrombus Resolution with Reduced Dose Apixaban. J Atr Fibrillation (2015) 0.75
Hemostasis in Intracranial Hemorrhage. Front Neurol (2017) 0.75
Anticoagulation in Atrial Fibrillation - Current Concepts. Arrhythm Electrophysiol Rev (2015) 0.75
Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. J Arrhythm (2017) 0.75
[Falls and dementia are not contraindications for anticoagulation in older adults with atrial fibrillation]. Z Gerontol Geriatr (2016) 0.75
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation (2007) 5.89
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke (2009) 3.89
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J (2012) 2.94
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol (2005) 1.97
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J (2013) 1.14
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J (2011) 0.92
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet (2016) 3.02
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J (2014) 1.51
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J (2016) 1.14
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J (2014) 0.94
High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol (2013) 0.92
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol (2014) 0.85
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med (2010) 0.81
Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother (2015) 0.80
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J (2015) 0.79
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur J Prev Cardiol (2014) 0.79
Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem (2016) 0.79
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J (2016) 0.76
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. Eur J Heart Fail (2016) 0.76
Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovasc Drugs Ther (2017) 0.75
Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough? Eur Heart J (2017) 0.75
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. Cardiovasc Drugs Ther (2017) 0.75
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. Eur J Heart Fail (2016) 0.75
Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. Int J Cardiol (2016) 0.75
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J (2017) 0.75
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. Am Heart J (2017) 0.75
Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol (2016) 0.75